Barinthus Biotherapeutics VACC Stock
Barinthus Biotherapeutics Price Chart
Barinthus Biotherapeutics VACC Financial and Trading Overview
| Barinthus Biotherapeutics stock price | 5 USD |
| Previous Close | 2.37 USD |
| Open | 2.35 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 2.35 - 2.5 USD |
| 52 Week Range | 2.02 - 7.45 USD |
| Volume | 9.49K USD |
| Avg. Volume | 49.68K USD |
| Market Cap | 95.54M USD |
| Beta (5Y Monthly) | 0.167278 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.33 USD |
VACC Valuation Measures
| Enterprise Value | -84865104 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1527778 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.1685338 |
| Price/Book (mrq) | 0.40219674 |
| Enterprise Value/Revenue | -2.814 |
| Enterprise Value/EBITDA | 3.619 |
Trading Information
Barinthus Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 0.167278 |
| 52-Week Change | -47.13% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.45 USD |
| 52 Week Low | 2.02 USD |
| 50-Day Moving Average | 2.4 USD |
| 200-Day Moving Average | 2.69 USD |
VACC Share Statistics
| Avg. Volume (3 month) | 49.68K USD |
| Avg. Daily Volume (10-Days) | 13.52K USD |
| Shares Outstanding | 38.37M |
| Float | 26.89M |
| Short Ratio | 0.58 |
| % Held by Insiders | 26.37% |
| % Held by Institutions | 26.98% |
| Shares Short | 15.76K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.040% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -51.18% |
| Operating Margin (ttm) | -82.34% |
| Gross Margin | -37.50% |
| EBITDA Margin | -77.77% |
Management Effectiveness
| Return on Assets (ttm) | -5.66% |
| Return on Equity (ttm) | -6.35% |
Income Statement
| Revenue (ttm) | 30.15M USD |
| Revenue Per Share (ttm) | 0.81 USD |
| Quarterly Revenue Growth (yoy) | -96.89% |
| Gross Profit (ttm) | N/A |
| EBITDA | -23452000 USD |
| Net Income Avi to Common (ttm) | -15434000 USD |
| Diluted EPS (ttm) | -0.42 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 191.33M USD |
| Total Cash Per Share (mrq) | 4.99 USD |
| Total Debt (mrq) | 10.65M USD |
| Total Debt/Equity (mrq) | 4.56 USD |
| Current Ratio (mrq) | 16.739 |
| Book Value Per Share (mrq) | 6.191 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11026000 USD |
| Levered Free Cash Flow (ttm) | 5.66M USD |
Profile of Barinthus Biotherapeutics
| Country | United States |
| State | N/A |
| City | Harwell |
| Address | Zeus Building |
| ZIP | OX11 0DF |
| Phone | 44 1865 818 808 |
| Website | https://www.vaccitech.co.uk |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Q&A For Barinthus Biotherapeutics Stock
What is a current VACC stock price?
Barinthus Biotherapeutics VACC stock price today per share is 5 USD.
How to purchase Barinthus Biotherapeutics stock?
You can buy VACC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Barinthus Biotherapeutics?
The stock symbol or ticker of Barinthus Biotherapeutics is VACC.
Which industry does the Barinthus Biotherapeutics company belong to?
The Barinthus Biotherapeutics industry is Biotechnology.
How many shares does Barinthus Biotherapeutics have in circulation?
The max supply of Barinthus Biotherapeutics shares is 38.55M.
What is Barinthus Biotherapeutics Price to Earnings Ratio (PE Ratio)?
Barinthus Biotherapeutics PE Ratio is 0.00000000 now.
What was Barinthus Biotherapeutics earnings per share over the trailing 12 months (TTM)?
Barinthus Biotherapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Barinthus Biotherapeutics company belong to?
The Barinthus Biotherapeutics sector is Healthcare.
Barinthus Biotherapeutics VACC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}